Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) has earned a consensus broker rating score of 0.00 () from the zero brokers that cover the company, Zacks Investment Research reports.
Zacks has also assigned Dipexium Pharmaceuticals an industry rank of .hide_lte_ie6 { display:none; } .hide_lte_ie7 { display:none; } .hide_lte_ie8 { display:none; } .hide_lte_ie9 { display:none; } .hide_lte_ie10 { display:none; } DPRX: NA – Brokerage Recommendations – Zacks.com var WIDGET_PATH_JS = ‘widget3.zacks.com’;var WIDGET3_PATH_JS = ‘widget3.zacks.com’;var PROTOCOL_JS = ‘https://’;var HTTP_PROTOCOL_JS = ‘https://’;var SITE_ROOT_PROTOCOL = ‘https://www.zacks.com/’;var STATIC_CONTENT_ROOT_JS = ‘https://staticx.zacks.com’;var STATIC_TUNER_IMAGE_ROOT = ‘https://staticx-tuner.zacks.com/images/’;var DEFAULT_HOST = ‘www.zacks.com’;var appendNumber = 4;var prependNumber = 1;var _qevents = _qevents || [];(function() {var elem = document.createElement(‘script’);elem.src = (document.location.protocol == “https:” ? “https://secure” : “http://edge”) + “.quantserve.com/quant.js”;elem.async = true;elem.type = “text/javascript”;var scpt = document.getElementsByTagName(‘script’)[0];scpt.parentNode.insertBefore(elem, scpt);})(); var googletag = googletag || {}; googletag.cmd = googletag.cmd || []; (function() { var gads = document.createElement(“script”); gads.async = true; gads.type = “text/javascript”; var useSSL = “https:” == document.location.protocol; gads.src = (useSSL ? “https:” : “http:”) + “//www.googletagservices.com/tag/js/gpt.js”; var node =document.getElementsByTagName(“script”)[0]; node.parentNode.insertBefore(gads, node); })(); var ybotq = ybotq || []; (function() { var js = document.createElement(“script”); js.src = “//cdn.yldbt.com/js/yieldbot.intent.js”; var node = document.getElementsByTagName(“script”)[0]; node.parentNode.insertBefore(js, node); })(); ybotq.push(function () { yieldbot.pub(“003d”); // Leaderboard-top yieldbot.defineSlot(“Leaderboard-top_101”); // Lrec-top yieldbot.defineSlot(“Lrec-top_201”); // Skyscraper-LefRail yieldbot.defineSlot(“Skyscraper-LefRail_301”); yieldbot.enableAsync(); yieldbot.go(); }); ybotq.push(function() { googletag.cmd.push(function() { googletag.pubads().set(“adsense_background_color”, “FFFFFF”); }); }); var slot_lookup = {}; ybotq.push(function() { googletag.cmd.push(function() { // Leaderboard-bottom googletag.defineSlot(“/2802258/ZComQuote-Leaderboard-bottom”, [728,90], “Leaderboard-bottom_102”).addService(googletag.pubads()); // Leaderboard-top slot_lookup[“Leaderboard-top_101”] = googletag.defineSlot(“/2802258/ZComQuote-Leaderboard-top”, [728,90], “Leaderboard-top_101”).addService(googletag.pubads()); // Lrec-top slot_lookup[“Lrec-top_201”] = googletag.defineSlot(“/2802258/ZComQuote-Lrec-top”, [[336,280],[300,250]], “Lrec-top_201”).addService(googletag.pubads()); // Lrec-middle googletag.defineSlot(“/2802258/ZComQuote-Lrec-middle”, [336,280], “Lrec-middle_202”).addService(googletag.pubads()); // Skyscraper-LefRail slot_lookup[“Skyscraper-LefRail_301”] = googletag.defineSlot(“/2802258/ZComQuote-Skyscraper-LefRail”, [160,600], “Skyscraper-LefRail_301”).addService(googletag.pubads()); // Leaderboard-top yieldbot.setSlotTargeting(“Leaderboard-top_101”, slot_lookup[“Leaderboard-top_101”]); // Lrec-top yieldbot.setSlotTargeting(“Lrec-top_201”, slot_lookup[“Lrec-top_201”]); // Skyscraper-LefRail yieldbot.setSlotTargeting(“Skyscraper-LefRail_301”, slot_lookup[“Skyscraper-LefRail_301”]); googletag.pubads(); googletag.pubads().enableAsyncRendering(); googletag.enableServices(); }); }); (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-2333136737514314”, enable_page_level_ads: true }); var _price_chart_compatibility_mode = true;$(document).ready(function() { window.charts.init_charts( ‘chart_form’, ‘chart_canvas’ );}); Join Sign In Member Sign In Keep Me Signed In What does “Remember Me” do? Forgot Password Create a New Account HomeStocksStocks+StocksZacks #1 RankZacks RankZacks Industry RankZacks Sector RankEquity ResearchMarketsFundsFunds+FundsMutual FundsETFsMutual Fund ScreenerETF ScreenerTop ETFsEarningsEarnings+EarningsEarnings CalendarEarnings ReleasesEarnings ESPEarnings ESP FilterScreeningScreening+ScreeningStock ScreenerMutual Fund ScreenerETF ScreenerPremium ScreensQuant MonitorResearch WizardFinanceFinance+Personal FinanceInsuranceInvestingMoney ManagingReal EstateRetirement PlanningTax InformationPortfolioPortfolio+My PortfolioCreate PortfolioEducationEducation+EducationStocksStyle ScoresFundsScreeningVideoPersonal TrainingServicesServices+Services OverviewZacks UltimateZacks Investor CollectionZacks PremiumZacks ConfidentialBlack Box TraderCounterstrikeETF InvestorHealthcare InnovatorsHome Run InvestorIncome InvestorInsider TraderLarge-Cap TraderMomentum TraderMethod for TradingOptions TraderReitmeister TraderResearch WizardShort ListStocks Under $10Surprise TraderTAZRTop 10 StocksValue Investor document.getElementById(‘search-q’).setAttribute(“autocomplete”, “off”); Menu HomeStocksStocks+StocksZacks #1 RankZacks RankZacks Industry RankZacks Sector RankEquity ResearchMarketsFundsFunds+FundsMutual FundsETFsMutual Fund ScreenerETF ScreenerTop ETFsEarningsEarnings+EarningsEarnings CalendarEarnings ReleasesEarnings ESPEarnings ESP FilterScreeningScreening+ScreeningStock ScreenerMutual Fund ScreenerETF ScreenerPremium ScreensQuant MonitorResearch WizardFinanceFinance+Personal FinanceInsuranceInvestingMoney ManagingReal EstateRetirement PlanningTax InformationPortfolioPortfolio+My PortfolioCreate PortfolioEducationEducation+EducationStocksStyle ScoresFundsScreeningVideoPersonal TrainingServicesServices+Services OverviewZacks UltimateZacks Investor CollectionZacks PremiumZacks ConfidentialBlack Box TraderCounterstrikeETF InvestorHealthcare InnovatorsHome Run InvestorIncome InvestorInsider TraderLarge-Cap TraderMomentum TraderMethod for TradingOptions TraderReitmeister TraderResearch WizardShort ListStocks Under $10Surprise TraderTAZRTop 10 StocksValue Investor Join Sign In Member Sign In Keep Me Signed In What does “Remember Me” do? Forgot Password Create a New Account Close this window Help ybotq.push(function () { googletag.cmd.push(function() { googletag.display(“Leaderboard-top_101”); }); }); You are being directed to ZacksTrade, a division out of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type out of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.OK Cancel Back to top more close Quotes & News Quote Overview Real Time Quotes Zacks News Partner News Zacks Research *Snapshot *Analyst Report *Style Scores *Detailed Estimates Comparison to Industry Zacks Experts View More Research Zacks Scorecard–> *Broker Recommendations Full Company Report Broker Digest Report Earnings Announcements Broker Reports Insiders Earnings Transcripts Charts *Price, Consensus and EPS Surprise *Fundamental Charts Comparative Interactive Charts Price and Consensus Price & EPS Surprise 12 Month EPS Broker Recommendations Financials Financial Overview Income Statements Balance Sheet Cash flow Statements Options Option Chain Options Greek Montage Access Zacks Data Feed ybotq.push(function () { googletag.cmd.push(function() { googletag.display(“Skyscraper-LefRail_301”); }); }); QUOTE_FEED_PATH = ‘quote-feed.zacks.com’; TICKER_JS_VAR = ‘DPRX’; Dipexium Pharmaceuticals, Inc. (DPRX) (Delayed Data from NSDQ) window.page_id=’quote’; Add to portfolio Trades from $3 $1.34 USD 1.34 144,261 +0.04 (2.92%) Updated Apr 19, 2017 03:59 PM ET Volume: 144,261 Open: $1.30 Prior Close: $1.30 Zacks Rank Style Scores Research Report –> Value: NA | Growth: NA | Momentum: NA | VGM: NA View All Zacks Rank #1 Strong Buys View All Zacks Rank #1 Strong Buys–> The Zacks Scorecard is a complimentary set out of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style. We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating: Zacks Style Score A based on the ratings given to related companies.
Separately, Zacks Investment Research lowered shares of Dipexium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 3rd.
Dipexium Pharmaceuticals (NASDAQ:DPRX) last announced its quarterly earnings results on Monday, April 17th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.02. On average, equities research analysts predict that Dipexium Pharmaceuticals will post ($1.57) EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Great Point Partners LLC purchased a new position in shares of Dipexium Pharmaceuticals during the third quarter worth about $2,594,000. 1492 Capital Management LLC raised its position in shares of Dipexium Pharmaceuticals by 85.1% in the third quarter. 1492 Capital Management LLC now owns 56,764 shares of the biotechnology company’s stock worth $823,000 after buying an additional 26,101 shares during the period. Timpani Capital Management LLC raised its position in shares of Dipexium Pharmaceuticals by 27.6% in the third quarter. Timpani Capital Management LLC now owns 81,815 shares of the biotechnology company’s stock worth $1,186,000 after buying an additional 17,691 shares during the period. State Treasurer State of Michigan purchased a new position in shares of Dipexium Pharmaceuticals during the third quarter worth about $181,000. Finally, Ardsley Advisory Partners purchased a new position in shares of Dipexium Pharmaceuticals during the third quarter worth about $178,000. Institutional investors and hedge funds own 25.61% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/04/22/zacks-dipexium-pharmaceuticals-inc-dprx-given-consensus-rating-of-by-analysts.html.
About Dipexium Pharmaceuticals
Dipexium Pharmaceuticals, Inc is a biopharmaceutical company. The Company was focused on the development and commercialization of Locilex (pexiganan cream 0.8%). The Company intends to develop and commercialize Locilex either directly or through one or more partnerships. The Company’s subsidiary is Dipexium Pharmaceuticals Ireland, Limited.
Get a free copy of the Zacks research report on Dipexium Pharmaceuticals (DPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
